Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,718,709
  • Shares Outstanding, K 150,621
  • Annual Sales, $ 257,890 K
  • Annual Income, $ -205,350 K
  • 60-Month Beta 1.17
  • Price/Sales 10.54
  • Price/Cash Flow N/A
  • Price/Book 50.96
Trade MOR with:

Options Overview Details

View History
  • Implied Volatility 22.31% ( -38.86%)
  • Historical Volatility 6.77%
  • IV Percentile 2%
  • IV Rank 1.82%
  • IV High 415.35% on 11/15/23
  • IV Low 15.03% on 03/22/24
  • Put/Call Vol Ratio 11.00
  • Today's Volume 24
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 1.86
  • Today's Open Interest 18,726
  • Open Int (30-Day) 30,903

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -45.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.87 +1.34%
on 04/03/24
18.20 -0.49%
on 04/09/24
-0.04 (-0.22%)
since 03/25/24
3-Month
10.02 +80.74%
on 01/26/24
18.31 -1.07%
on 03/12/24
+8.24 (+83.49%)
since 01/25/24
52-Week
4.18 +332.74%
on 11/22/23
18.31 -1.07%
on 03/12/24
+12.99 (+253.71%)
since 04/25/23

Most Recent Stories

More News
MorphoSys AG Reports First Quarter 2023 Financial Results

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023 .

MOR : 18.13 (+0.44%)
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final five-year follow-up data from the Phase 2 L-MIND study showing that...

MOR : 18.13 (+0.44%)
INCY : 51.16 (-1.12%)
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

INCY : 51.16 (-1.12%)
CRSP : 53.75 (-3.41%)
MOR : 18.13 (+0.44%)
CERT : 16.30 (-0.91%)
Why Shares of MorphoSys Are Up Wednesday

The company's phase 3 trial for a lead therapy is ahead of schedule.

MOR : 18.13 (+0.44%)
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

MOR : 18.13 (+0.44%)
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

Conference call and webcast (in English) tomorrow, November 17, 2022, at 2:00pm CET (1pm GMT/8:00am ET)

MOR : 18.13 (+0.44%)
Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others

Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.

BIIB : 202.53 (+0.27%)
RHHBY : 30.0050 (-1.75%)
LLY : 723.51 (-1.19%)
MOR : 18.13 (+0.44%)
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of...

MOR : 18.13 (+0.44%)
TEVA : 13.26 (+1.92%)
MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript

MOR earnings call for the period ending June 30, 2022.

MOR : 18.13 (+0.44%)
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

Conference call and webcast (in English) tomorrow, August 4, 2022, at 2:00pm CEST (1pm BST/8:00am EDT)

MOR : 18.13 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG...

See More

Key Turning Points

3rd Resistance Point 18.17
2nd Resistance Point 18.13
1st Resistance Point 18.09
Last Price 18.13
1st Support Level 18.01
2nd Support Level 17.97
3rd Support Level 17.93

See More

52-Week High 18.31
Last Price 18.13
Fibonacci 61.8% 12.91
Fibonacci 50% 11.24
Fibonacci 38.2% 9.58
52-Week Low 4.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar